(Q48629242)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22389413%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

title

MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22389413%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22389413%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

author name string

Luigi M E Grimaldi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22389413%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Gaetano Vitello

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22389413%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Giovanna Borriello

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22389413%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Federica Fubelli

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22389413%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Carlo Pozzilli

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22389413%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

publication date

2 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22389413%20AND%20SRC:MED&resulttype=core&format=json

Multiple Sclerosis Journal

25 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22389413%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22389413%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22389413%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

page(s)

1337-1339

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22389413%20AND%20SRC:MED&resulttype=core&format=json

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

25 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439438

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439438

Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439438

Three years of experience: the Italian registry and safety data update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439438

Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439438

A controlled trial of natalizumab for relapsing multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1352458512439438